Inflammatix Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
73
- Latest Deal Type
-
Series E
- Latest Deal Amount
-
$57M
- Investors
-
20
Inflammatix General Information
Description
Developer of molecular diagnostic tests designed to interpret the immune system to diagnose acute infections and assess illness severity. The company's tests measure specific messenger RNA markers in blood samples to provide bacterial and viral infection likelihood and severity scores, enabling emergency departments to make timely clinical decisions and improve patient management with data-driven insights.
Contact Information
Website
www.inflammatix.comCorporate Office
- 540 Oakmead Parkway
- Sunnyvale, CA 94085
- United States
Corporate Office
- 540 Oakmead Parkway
- Sunnyvale, CA 94085
- United States
Inflammatix Timeline
Inflammatix Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Later Stage VC (Series E) | 12-Sep-2024 | $57M | Completed | Product Development | ||
| 12. Secondary Transaction - Private | Completed | Product Development | ||||
| 11. Grant | 01-Jul-2023 | Completed | Product Development | |||
| 10. Grant | 11-Nov-2021 | Completed | Product Development | |||
| 9. Later Stage VC (Series D) | 14-Sep-2021 | Completed | Product Development | |||
| 8. Accelerator/Incubator | 22-Jun-2020 | Completed | Product Development | |||
| 7. Later Stage VC (Series C) | 10-Jan-2020 | Completed | Product Development | |||
| 6. Grant | 14-Nov-2019 | Completed | Product Development | |||
| 5. Early Stage VC (Series B) | 18-Oct-2018 | $17.9M | $22M | Completed | Product Development | |
| 4. Accelerator/Incubator | 31-Mar-2017 | $4.1M | Completed | Product Development |
Inflammatix Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | 8,250,918 | $0.000010 | 8% | $1.73 | $1.73 | 1x | $1.73 | 11.26% |
| Series A | 6,192,310 | $0.000010 | 8% | $0.67 | $0.67 | 1x | $0.67 | 8.45% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Inflammatix Comparisons
Industry
Financing
Details
Inflammatix Competitors (5)
One of Inflammatix’s 5 competitors is Immunexpress, a Venture Capital-Backed company based in Seattle, WA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Immunexpress | Venture Capital-Backed | Seattle, WA | ||||
| ExGen Dx | Venture Capital-Backed | Birmingham, United Kingdom | ||||
| CytoVale | Venture Capital-Backed | South San Francisco, CA | ||||
| Sense Biodetection | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Autogenomics | Formerly VC-backed | Carlsbad, CA |
Inflammatix Patents
Inflammatix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260249299-A1 | Mastermix integration into cartridge-based in vitro diagnostics device | Pending | 21-Feb-2025 | ||
| WO-2026178224-A1 | Mastermix integration into cartridge-based in vitro diagnostics device | Pending | 21-Feb-2025 | ||
| EP-4608557-A1 | A fluidic device and methods for characterization of an infection or other condition | Pending | 24-Oct-2022 | ||
| WO-2024091936-A1 | A fluidic device and methods for characterization of an infection or other condition | Inactive | 24-Oct-2022 | ||
| US-20240132963-A1 | Fluidic device and methods for characterization of an infection or other condition | Pending | 24-Oct-2022 | C12Q1/6883 |
Inflammatix Signals
Inflammatix Investors (20)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| OSF Healthcare | Corporation | Minority | ||
| Raw Ventures | Venture Capital | Minority | ||
| Vesalius Biocapital Partners | Venture Capital | Minority | ||
| Defense Advanced Research Projects Agency | Government | |||
| National Institutes of Health | Government |
Inflammatix FAQs
-
When was Inflammatix founded?
Inflammatix was founded in 2016.
-
Where is Inflammatix headquartered?
Inflammatix is headquartered in Sunnyvale, CA.
-
What is the size of Inflammatix?
Inflammatix has 73 total employees.
-
What industry is Inflammatix in?
Inflammatix’s primary industry is Diagnostic Equipment.
-
Is Inflammatix a private or public company?
Inflammatix is a Private company.
-
What is Inflammatix’s current revenue?
The current revenue for Inflammatix is .
-
How much funding has Inflammatix raised over time?
Inflammatix has raised $213M.
-
Who are Inflammatix’s investors?
OSF Healthcare, Raw Ventures, Vesalius Biocapital Partners, Defense Advanced Research Projects Agency, and National Institutes of Health are 5 of 20 investors who have invested in Inflammatix.
-
Who are Inflammatix’s competitors?
Immunexpress, ExGen Dx, CytoVale, Sense Biodetection, and Autogenomics are competitors of Inflammatix.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process